District Of Columbia is currently home to 861 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Washington, Washington, D.C., Washington DC and Washington, Dc. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Development of Clinical Database of Individuals With Smith-Magenis Syndrome and Sleep Disturbances
NCT03154697
Recruiting
This database will be used to better understand the sleep problems of people with SMS. This clinical database will be a part of a larger Smith-Magenis Patient Registry used to create an awareness campaign around SMS and the sleep disturbances that are characteristic of the disorder.
Gender:
ALL
Ages:
Between 3 years and 65 years
Trial Updated:
03/19/2024
Locations: Vanda Pharmaceuticals, Washington, District of Columbia
Conditions: Sleep Disturbances in Smith-Magenis Syndrome
Register for Updates
Outcomes of the Nanoscopic Partial Meniscectomy Versus Standard Arthroscopic Partial Meniscectomy
NCT05617807
Recruiting
Standard arthroscopy has been the gold standard for treatment of meniscus tears since the 1980's. The purpose of this study is to analyze the clinical outcomes of using the smaller diameter Nanoscope for partial menisectomy. The authors hypothesize that the Nanoscopic partial menisectomy patients will have less pain and return function faster than standard arthroscopy.
Gender:
ALL
Ages:
65 years and below
Trial Updated:
03/18/2024
Locations: MedStar Washington Hospital Center, Washington, District of Columbia
Conditions: Meniscus Tear
Register for Updates
Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)
NCT04443348
Recruiting
This research trial is studying a combination of neoadjuvant radiotherapy (RT), immunotherapy (pembrolizumab) and chemotherapy for lymph node-positive, triple negative (TN) or hormone receptor positive/HER2-negative breast cancer. The names of the study interventions involved in this study are: * Radiation Therapy (RT) * Immunotherapy: Pembrolizumab (MK-3475) * Chemotherapies: * Paclitaxel * Doxorubicin (also called Adriamycin) * Cyclophosphamide * Carboplatin (optional, and in TN onl... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2024
Locations: Sibley Memorial Hospital, Washington, District of Columbia
Conditions: Triple Negative Breast Cancer, Hormone Receptor Positive (HR+), HER2-negative Breast Cancer, Biopsy-proven, Positive Lymph Node(s)
Register for Updates
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
NCT04488081
Recruiting
The goal of this project is to rapidly screen promising agents, in the setting of an adaptive platform trial, for treatment of critically ill COVID-19 patients. In this phase 2 platform design, agents will be identified with a signal suggesting a big impact on reducing mortality and the need for, as well as duration, of mechanical ventilation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/15/2024
Locations: Georgetown University, Washington, District of Columbia
Conditions: COVID-19
Register for Updates
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
NCT06322693
Recruiting
This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of TSR-022 in combination with TSR-042 or docetaxel and as monotherapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: GSK Investigational Site, Washington, District of Columbia
Conditions: Neoplasms
Register for Updates
NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors
NCT05661201
Recruiting
The goal of this clinical trial is to learn about the safety of NEROFE and doxorubicin and how well it works in patients with advanced/unresectable or metastatic solid KRAS-mutated and ST-positive solid tumors. The main question it aims to answer is to find the recommended dose and scheduled for the combination of NEROFE and doxorubicin. Participants will receive weekly doses of NEROFE and doxorubicin.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2024
Locations: Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia
Conditions: Solid Tumor, KRAS Mutation-Related Tumors
Register for Updates
Sistas Informing Sistas on Topics About AIDS and Prevention (SISTA-P)
NCT06307028
Recruiting
In this project, the investigators will provide a new HIV prevention training and empowerment sessions to Black women in Washington D.C. who are at high risk for getting HIV. This training is tailored to the experience of Black women and seeks to reduce the high HIV transmission rates in the Black community.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/06/2024
Locations: The Women's Collective, Washington, District of Columbia
Conditions: Health Behavior, Risky, Health Knowledge, Attitudes, Practice, Health-Related Behavior
Register for Updates
Tobacco Education and Lung Health Study (TEAL)
NCT06290869
Recruiting
Primary Objective To compare two smoking cessation interventions among individuals undergoing lung cancer screening. Primary outcomes are: 3-month self-reported abstinence from cigarettes and 6-month self-reported and bioverified abstinence from cigarettes. Secondary Objectives 1) To evaluate reach and engagement overall and by subgroup (e.g., race and ethnicity, underinsured, readiness to quit). 2) To conduct an economic analysis to evaluate intervention costs from the health system perspectiv... Read More
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
03/03/2024
Locations: Georgetown University Medical Center, Washington, District of Columbia
Conditions: Smoking Cessation
Register for Updates
Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas
NCT05130866
Recruiting
This is a two-staged, Phase 2/3, randomized, multi-center study to investigate the efficacy and safety of REC-2282 in patients with progressive NF2 mutated meningiomas.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
02/29/2024
Locations: Children's National Hospital, Washington, District of Columbia
Conditions: Neurofibromatosis Type 2
Register for Updates
Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort
NCT01574053
Recruiting
Enroll-HD is a longitudinal, observational, multinational study that integrates two former Huntington's disease (HD) registries-REGISTRY in Europe, and COHORT in North America and Australasia-while also expanding to include sites in Latin America. More than 30,000 participants have now enrolled into the study. With annual assessments and no end date, Enroll-HD has built a large and rich database of longitudinal clinical data and biospecimens that form the basis for studies developing tools and b... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/26/2024
Locations: Georgetown University, Washington, District of Columbia
Conditions: Huntington's Disease
Register for Updates
Development and Testing of a Pediatric Cervical Spine Injury Risk Assessment Tool
NCT05049330
Recruiting
Cervical spine injuries (CSI) are serious, but rare events in children. Spinal precautions (rigid cervical collar and immobilization on a longboard) in the prehospital setting may be beneficial for children with CSI, but are poorly studied. In contrast, spinal precautions for pediatric trauma patients without CSI are common and may be associated with harm. Spinal precautions result in well-documented adverse physical and physiological sequelae. Of substantial concern is that the mere presence of... Read More
Gender:
ALL
Ages:
18 years and below
Trial Updated:
02/21/2024
Locations: Children's National Medical Center, Washington, District of Columbia
Conditions: Cervical Spine Injury
Register for Updates
A Study to Investigate Leramistat in Patients With IPF
NCT05951296
Recruiting
To compare the effect of daily oral dosing of leramistat over 12 weeks with placebo in participants aged 40 years or older with idiopathic pulmonary fibrosis (IPF).
Gender:
ALL
Ages:
40 years and above
Trial Updated:
02/16/2024
Locations: MedStar Georgetown University Hospital, Washington, District of Columbia
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates